Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2020 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.
PLoS One. 2022 Apr 29;17(4):e0267543. doi: 10.1371/journal.pone.0267543. eCollection 2022.
PLoS One. 2022.
PMID: 35486574
Free PMC article.
177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma.
Malenge MM, Patzke S, Ree AH, Stokke T, Ceuppens P, Middleton B, Dahle J, Repetto-Llamazares AHV.
Malenge MM, et al.
J Nucl Med. 2020 Oct;61(10):1468-1475. doi: 10.2967/jnumed.119.237230. Epub 2020 Apr 3.
J Nucl Med. 2020.
PMID: 32245896
Free PMC article.
Item in Clipboard
Combination of 177 Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma.
Repetto-Llamazares AHV, Malenge MM, O'Shea A, Eiríksdóttir B, Stokke T, Larsen RH, Dahle J.
Repetto-Llamazares AHV, et al. Among authors: malenge mm.
Eur J Haematol. 2018 Oct;101(4):522-531. doi: 10.1111/ejh.13139. Epub 2018 Aug 31.
Eur J Haematol. 2018.
PMID: 29993152
Item in Clipboard
Cite
Cite